A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days.
About
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing CD19-CAR T, as the lead product candidate, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform may offer potentially curative therapies for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters are located in
Contacts
Chief Financial Officer
investors@cabalettabio.com
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com
![](https://ml.globenewswire.com/media/OGQ2MTQ0YzQtZGY5Zi00ZGE3LTk2NDctZmY4MDNhNTdlYzU4LTExMzY2MDE=/tiny/Cabaletta-Bio.png)
2023 GlobeNewswire, Inc., source